These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11785037)

  • 1. [Dopamine agonists situation in Parkinson disease].
    Barbanoj M; Campos Arillo VM; Giménez-Roldán S; Kulisevsky J; Linazasoro Cristóbalampos G; Luquin Piudo MR; Vela Desojo L
    Rev Neurol; 2001 Dec 1-15; 33(11):1071-93. PubMed ID: 11785037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 3. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ropinirol: a new dopamine agonist in the treatment of Parkinson's disease].
    Giménez-Roldán S
    Neurologia; 1997 Oct; 12(8):354-61. PubMed ID: 9471165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of dopaminergic agonists].
    Rascol O; Montastruc JL
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():98-104. PubMed ID: 10916043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of functional age on the use of dopamine agonists in patients with Parkinson disease.
    Silver D
    Neurologist; 2006 Jul; 12(4):214-23. PubMed ID: 16832240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.